AADAC Rabbit Polyclonal Antibody

Specifications

Product Data
Applications	IHC, WB
Recommend Dilution	WB: 500-2000 WB positive control: Human fetal liver and liver cancer tissue IHC: 25-100 Positive control: Human colon cancer Predicted cell location: Cytoplasm
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Immunogen	Fusion protein corresponding to C terminal 250 amino acids of human arylacetamide deacetylase
Formulation	PBS pH7.3, 0.05% NaN3, 50% glycerol
Concentration	lot specific
Purification	Antigen affinity purification
Conjugation	Unconjugated
Storage Condition	Store at -20°C as received.
Predicted Protein Size	46 kDa
Gene Name	arylacetamide deacetylase
Database Link	NP_001077 Entrez Gene 13 Human UniProt ID P22760
Background	Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase; which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide; which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.
Synonyms	CES5A1; DAC
Reference Data
Protein Families	Druggable Genome, Transmembrane

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.